滚动资讯
FierceBiotechGilead loosens ties to Arcus after TIGIT dream finally ends in phase 3 failureFierceBiotechWith $50M from Flagship Pioneering, Serif strives to write new chapter for DNA medicinesLonza NewsFDA-backed drug project tests modeling to reduce some human studies - Stock TitanThermo FisherSaladax Biomedical and Thermo Fisher Scientific Partner on Global Distribution of Drug Monitoring Assays - Clinical Lab ProductsThermo FisherTD Cowen Lowers Thermo Fisher (TMO) Price Target, Keeps Buy Rating - Yahoo FinanceLonza NewsLonza Group AG stock (CH0013841017): Is its biopharma contract model resilient enough for new growth - AD HOC NEWSFierceBiotechReplimmune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection10x Genomics Blog10x Genomics debuts Atera, a new platform to redefine how biology is measured and understood at AACR 2026 - SelectScienceIlluminaClinical Genomic Market: Growth and Outlook Driven by Illumina, - openPR.comThermo FisherAssessing Thermo Fisher Scientific (TMO) Valuation After New PCR Launch And Data Partnerships - simplywall.stCuriosis Inc.Working capital per share of Curiosis, Inc. – KRX:494120 - TradingViewWatersWaters Corporation Schedules First Quarter 2026 Earnings Conference Call - ChartMill
Waters 2025年12月18日

沃特世公司股票在财报发布前是否值得安全买入——交易量总结与AI预测摆动交易精选

沃特世公司股票在财报发布前是否值得安全买入——交易量总结与AI预测摆动交易精选

原文
暂时没有全文，请查看原始来源。